• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Healthcare Law or Not, Insurance Is Set to Change

Article

As the Supreme Court prepares to rule on the federal health overhaul, health insurers are in the spotlight. The law has been reshaping the health insurers' business—requiring, for instance, that they spend a set share of premium dollars on health care, or send refunds to customers if they fall short—and this month could see the law vanish or change markedly.

Read the full story: http://tinyurl.com/bn8dqzb

Source: The Wall Street Journal

Related Videos
Manjool Shah, MD
Hearn Jay Cho, MD, PhD
Nicoletta Colombo, MD, PhD
Screenshot of an interview with Stephen Nicholls, MBBS, PhD
Screenshot of an interview with Martha Gulati, MD
Screenshot of an interview with Vallerie McLaughlin, MD
Nicoletta Colombo, MD, PhD
Brigid Groves, PharmD, MS, vice president, professional affairs, American Pharmacists Association
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Related Content
The OCEANIC-STROKE subgroup analysis findings, in tandem with the main results presented at ISC 2026, suggest that targeting factor XIa could be a safe way to intensify antithrombotic therapy following noncardioembolic stroke, regardless of underlying etiology. | Image credit: jolygon - stock.adobe.com

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

February 6th 2026
Article

OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke risk across noncardioembolic subtypes without increasing major bleeding risk.

Read More

Managed Care Cast Square thumbnail

Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care

November 25th 2025
Podcast

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Listen

Asundexian with standard antiplatelet therapy helped reduce the chances of a recurrent stroke without increasing the risk of bleeding, according to the OCEANIC-STROKE trial. | Image credit: Studio Multiverse - stock.adobe.com

Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial

February 5th 2026
Article

OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase.

Read More

Managed Care Cast Square thumbnail

Managed Care Cast Presents: Leveraging Topical Therapies for Pediatric Atopic Dermatitis

October 30th 2025
Podcast

Experts discuss how topical therapies effectively manage atopic dermatitis in pediatric patients, enhancing outcomes and addressing unique challenges.

Listen

Many solutions to improve disparities in stroke care come down to appropriate tailoring for the target system and community. | Image credit: BJP7images - stock.adobe.com

Closing Gaps in Stroke Care Starts With Defining the US Health Care Safety Net

February 5th 2026
Article

Clearer definitions, tailored programs and policies, and telestroke care could help close rural stroke care disparities.

Read More

Excellent functional outcomes were more common among patients who received adjunctive alteplase vs thrombectomy alone, with a 15% adjusted risk difference. | Image credit: vegefox - stock.adobe.com

Intraarterial Alteplase After Thrombectomy May Improve Stroke Recovery: CHOICE2

February 4th 2026
Article

CHOICE2 found intraarterial alteplase after thrombectomy raised the odds of excellent outcomes following large-vessel occlusion ischemic stroke.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.